EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

Resistance to anti-HER2 therapies in breast cancer remains a significant clinical challenge. Here, the authors demonstrate that EZH2 regulates response to HER2-targeting therapies in breast cancer, in part, by modulating the expression of PPP2R2B.

Guardado en:
Detalles Bibliográficos
Autores principales: Yi Bao, Gokce Oguz, Wee Chyan Lee, Puay Leng Lee, Kakaly Ghosh, Jiayao Li, Panpan Wang, Peter E. Lobie, Sidse Ehmsen, Henrik J. Ditzel, Andrea Wong, Ern Yu Tan, Soo Chin Lee, Qiang Yu
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Q
Acceso en línea:https://doaj.org/article/d3c09063233a46f7b4d0dbd7cf8055f0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!